{"id":"low-dose-acetazolamide","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Paresthesia (tingling in extremities)"},{"rate":"5-20","effect":"Altered taste (especially carbonated beverages)"},{"rate":"10-30","effect":"Mild diuresis"},{"rate":"5-15","effect":"Metabolic acidosis"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL20","moleculeType":"Small molecule","molecularWeight":"222.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetazolamide is a carbonic anhydrase inhibitor that decreases aqueous humor production in the eye and increases renal bicarbonate excretion, leading to mild metabolic acidosis. At low doses, it is used primarily to reduce intraocular pressure in glaucoma and to prevent or treat altitude sickness by promoting respiratory alkalosis and diuresis.","oneSentence":"Acetazolamide inhibits carbonic anhydrase to reduce bicarbonate reabsorption in the kidney, promoting diuresis and alkalinizing urine while lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:15.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Altitude sickness prevention and treatment"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT05707442","phase":"PHASE3","title":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":"Idiopathic Intracranial Hypotension, Venous Sinus Stenosis","enrollment":74},{"nctId":"NCT04726982","phase":"PHASE4","title":"Optimal Dosage of Acetazolamide for OSA Treatment","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2021-04-20","conditions":"Obstructive Sleep Apnea","enrollment":91},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT06146101","phase":"PHASE2, PHASE3","title":"RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incannex Healthcare Ltd","startDate":"2024-05-02","conditions":"Obstructive Sleep Apnea","enrollment":560},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT03501966","phase":"PHASE3","title":"Surgical Idiopathic Intracranial Hypertension Treatment Trial","status":"TERMINATED","sponsor":"Jaeb Center for Health Research","startDate":"2019-02-06","conditions":"Idiopathic Intracranial Hypertension","enrollment":7},{"nctId":"NCT03963336","phase":"EARLY_PHASE1","title":"Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2017-07-22","conditions":"Idiopathic Intracranial Hypertension","enrollment":48},{"nctId":"NCT01973335","phase":"PHASE4","title":"Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2013-11","conditions":"Heart Failure","enrollment":34},{"nctId":"NCT01993667","phase":"PHASE4","title":"Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-03","conditions":"Prophylaxis of Acute Mountain Sickness","enrollment":130},{"nctId":"NCT03779594","phase":"PHASE2","title":"Acetazolamide for Treating NPH in Shunt-candidates Patients","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2018-12","conditions":"Normal Pressure Hydrocephalus","enrollment":15},{"nctId":"NCT01003639","phase":"PHASE2, PHASE3","title":"Idiopathic Intracranial Hypertension Treatment Trial","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2010-01","conditions":"Idiopathic Intracranial Hypertension","enrollment":165},{"nctId":"NCT02670096","phase":"NA","title":"A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-01","conditions":"Sleep Apnea","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diamox"],"phase":"marketed","status":"active","brandName":"Low Dose Acetazolamide","genericName":"Low Dose Acetazolamide","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetazolamide inhibits carbonic anhydrase to reduce bicarbonate reabsorption in the kidney, promoting diuresis and alkalinizing urine while lowering intraocular pressure. Used for Open-angle glaucoma, Altitude sickness prevention and treatment, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}